GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Results of Operations and Financial Condition

Item2.02 Results of Operations and Financial Condition.

On May15, 2017, Galectin Therapeutics Inc. (Galectin
Therapeutics) issued a press release announcing its results of
operations and financial condition for the three months ended
May15, 2017 and provided a business update. Galectin hereby
incorporates by reference herein the information set forth in its
press release dated May15, 2017 (the Press Release), a copy of
which is attached hereto as Exhibit99.1.

Except for the historical information contained in this report,
the statements made by Galectin Therapeutics are forward looking
statements that involve risks and uncertainties. All such
statements are subject to the safe harbor created by the Private
Securities Litigation Reform Act of 1995. Galectin Therapeutics
future financial performance could differ significantly from the
expectations of management and from results expressed or implied
in the Press Release. Forward-looking statements in the Press
Release are subject to certain risks and uncertainties described
in the Press Release. For further information on other risk
factors, please refer to the Risk Factors contained in Galectin
Therapeutics Annual Report on Form 10-K for the fiscal year ended
December31, 2016, as filed with the Securities and Exchange
Commission, and its subsequent filings with the SEC.

The information in this Item2.02 is being furnished, not filed,
to Item2.02 of Form 8-K. Accordingly, the information in Item2.02
of this report, including the Press Release attached hereto as
Exhibit 99.1, will not be incorporated by reference into any
registration statement filed by Galectin under the Securities Act
of 1933, as amended, unless specifically identified therein as
being incorporated therein by reference.

SECTION9 FINANCIAL STATEMENTS AND EXHIBITS

Item9.01 Financial Statements and Exhibits.

2

About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Recent Trading Information

GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) closed its last trading session down -0.03 at 2.72 with 120,398 shares trading hands.